This review highlights advancements in RSV immunization strategies and their implications for infection control.
Respiratory syncytial virus (RSV) is a negative‐sense RNA virus belonging to the genus Orthopneumovirus within the family Pneumoviridae . It is a leading cause of lower respiratory tract infections in infants and young children worldwide and also poses a significant health burden to elderly and immunocompromised individuals, with a clinical severity comparable to that of seasonal influenza. For decades, RSV‐specific prevention and treatment strategies remained limited; however, recent breakthroughs in both vaccine‐based active immunization and antibody‐mediated passive immunization have fundamentally reshaped the landscape of RSV prevention. This review provides a comprehensive overview of the current understanding and future challenges posed by RSV infection, integrating the latest advances in virology, epidemiology, clinical diagnostics, prevention strategies, and therapeutic innovations.
No takes yet. Share an insight, caveat, or question.
Cheng et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: